

# Pieter L Jager

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9112427/publications.pdf>

Version: 2024-02-01

83  
papers

5,334  
citations

109137

35  
h-index

82410

72  
g-index

84  
all docs

84  
docs citations

84  
times ranked

4984  
citing authors

#	ARTICLE	IF	CITATIONS
1	Does fractional flow reserve overestimate severity of LAD lesions?. Journal of Nuclear Cardiology, 2020, 27, 1306-1313.	1.4	7
2	Small-voxel reconstructions significantly influence SUVs in PET imaging. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 1751-1752.	3.3	7
3	Coronary calcium score influences referral for invasive coronary angiography after normal myocardial perfusion SPECT. Journal of Nuclear Cardiology, 2019, 26, 602-612.	1.4	8
4	SUV variability in EARL-accredited conventional and digital PET. EJNMMI Research, 2019, 9, 106.	1.1	18
5	Value of automatic patient motion detection and correction in myocardial perfusion imaging using a CZT-based SPECT camera. Journal of Nuclear Cardiology, 2018, 25, 419-428.	1.4	16
6	Anatomically and functionally relevant coronary stenoses in patients with normal single-photon emission computed tomography but persistent stable angina. European Heart Journal Cardiovascular Imaging, 2018, 19, 1327-1333.	0.5	2
7	Diagnostic implications of a small-voxel reconstruction for loco-regional lymph node characterization in breast cancer patients using FDG-PET/CT. EJNMMI Research, 2018, 8, 3.	1.1	12
8	Sequential SPECT/CT imaging for detection of coronary artery disease in a large cohort: evaluation of the need for additional imaging and radiation exposure. Journal of Nuclear Cardiology, 2017, 24, 212-223.	1.4	7
9	Sequential SPECT/CT imaging starting with stress SPECT in patients with left bundle branch block suspected for coronary artery disease. European Radiology, 2017, 27, 178-187.	2.3	0
10	Changes in cardiovascular medication after coronary artery calcium scanning and normal single photon emission computed tomography myocardial perfusion imaging in symptomatic patients. American Heart Journal, 2017, 186, 56-62.	1.2	5
11	Prognostic Value of Myocardial Perfusion Imaging with a Cadmium-Zinc-Telluride SPECT Camera in Patients Suspected of Having Coronary Artery Disease. Journal of Nuclear Medicine, 2017, 58, 1459-1463.	2.8	26
12	Prognostic Value of Coronary Artery Calcium Scoring in Addition to Single-Photon Emission Computed Tomographic Myocardial Perfusion Imaging in Symptomatic Patients. Circulation: Cardiovascular Imaging, 2016, 9, .	1.3	84
13	Impact of Gender on the Prognostic Value of Coronary Artery Calcium in Symptomatic Patients With Normal Single-Photon Emission Computed Tomography Myocardial Perfusion. American Journal of Cardiology, 2016, 118, 1611-1615.	0.7	4
14	Technical note: how to determine the FDG activity for tumour PET imaging that satisfies European guidelines. EJNMMI Physics, 2016, 3, 22.	1.3	22
15	Current generation time-of-flight 18F-FDG PET/CT provides higher SUVs for normal adrenal glands, while maintaining an accurate characterization of benign and malignant glands. Annals of Nuclear Medicine, 2016, 30, 145-152.	1.2	10
16	Prognostic value of normal stress-only myocardial perfusion imaging: a comparison between conventional and CZT-based SPECT. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 296-301.	3.3	27
17	Improving the Detection of Small Lesions Using a State-of-the-Art Time-of-Flight PET/CT System and Small-Voxel Reconstructions. Journal of Nuclear Medicine Technology, 2015, 43, 21-27.	0.4	35
18	Minimizing Patient-Specific Tracer Dose in Myocardial Perfusion Imaging Using CZT SPECT. Journal of Nuclear Medicine Technology, 2015, 43, 36-40.	0.4	19

#	ARTICLE	IF	CITATIONS
19	Impact of image processing in the detection of ischaemia using CZT-SPECT/CT. <i>Nuclear Medicine Communications</i> , 2015, 36, 60-68.	0.5	5
20	Influence of proton-pump inhibitors on stomach wall uptake of <sup>99m</sup> Tc-tetrofosmin in cadmium-zinc-telluride SPECT myocardial perfusion imaging. <i>Nuclear Medicine Communications</i> , 2015, 36, 143-147.	0.5	10
21	Myocardial perfusion imaging in stable symptomatic patients with extensive coronary atherosclerosis. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 41, 136-143.	3.3	12
22	Myocardial perfusion imaging with a cadmium zinc telluride-based gamma camera versus invasive fractional flow reserve. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 41, 956-962.	3.3	32
23	The influence of coronary calcium score on the interpretation of myocardial perfusion imaging. <i>Journal of Nuclear Cardiology</i> , 2014, 21, 368-374.	1.4	23
24	Prevalence, location, and extent of significant coronary artery disease in patients with normal myocardial perfusion imaging. <i>Journal of Nuclear Cardiology</i> , 2014, 21, 284-290.	1.4	18
25	Coronary Artery Calcium Scoring to Exclude Flow-Limiting Coronary Artery Disease in Symptomatic Stable Patients at Low or Intermediate Risk. <i>Radiology</i> , 2013, 269, 77-83.	3.6	47
26	PET/CT using <sup>18</sup> F-FDOPA provides improved staging of carcinoid tumor patients in a Canadian setting. <i>Nuclear Medicine Communications</i> , 2012, 33, 322-330.	0.5	17
27	Development of a radioiodinated apoptosis-inducing ligand, rhTRAIL, and a radiolabelled agonist TRAIL receptor antibody for clinical imaging studies. <i>British Journal of Pharmacology</i> , 2012, 165, 2203-2212.	2.7	16
28	Impact of a new ultrafast CZT SPECT camera for myocardial perfusion imaging: fewer equivocal results and lower radiation dose. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2012, 39, 1048-1055.	3.3	86
29	Somatostatin receptor scintigraphy might be useful for detecting skeleton abnormalities in patients with multiple myeloma and plasmacytoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2010, 37, 124-130.	3.3	24
30	Amyloid load in fat tissue reflects disease severity and predicts survival in amyloidosis. <i>Arthritis Care and Research</i> , 2010, 62, 296-301.	1.5	30
31	Biodistribution of <sup>89</sup> Zr-trastuzumab and PET Imaging of HER2-Positive Lesions in Patients With Metastatic Breast Cancer. <i>Clinical Pharmacology and Therapeutics</i> , 2010, 87, 586-592.	2.3	685
32	Combined Vertebral Fracture Assessment and Bone Mineral Density Measurement: A Patient-friendly New Tool with an Important Impact on the Canadian Risk Fracture Classification. <i>Canadian Association of Radiologists Journal</i> , 2010, 61, 194-200.	1.1	24
33	Vertebral Fracture Assessment in Supine Position: Comparison by Using Conventional Semiquantitative Radiography and Visual Radiography. <i>Radiology</i> , 2009, 251, 822-828.	3.6	54
34	<sup>6</sup> -[F-18]Fluoro-Dihydroxyphenylalanine Positron Emission Tomography Is Superior to Conventional Imaging with <sup>123</sup> I-Metaiodobenzylguanidine Scintigraphy, Computer Tomography, and Magnetic Resonance Imaging in Localizing Tumors Causing Catecholamine Excess. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009, 94, 3922-3930.	1.8	153
35	[ <sup>18</sup> F]FLT-PET and [ <sup>18</sup> F]FDG-PET in the evaluation of radiotherapy for laryngeal cancer. <i>Oral Oncology</i> , 2009, 45, e211-e215.	0.8	17
36	Molecular imaging in neuroendocrine tumors: Molecular uptake mechanisms and clinical results. <i>Critical Reviews in Oncology/Hematology</i> , 2009, 71, 199-213.	2.0	135

#	ARTICLE	IF	CITATIONS
37	The diagnostic value of <sup>124</sup> I-PET in patients with differentiated thyroid cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2008, 35, 958-965.	3.3	107
38	Utility of an intraoperative gamma probe in the surgical management of secondary or tertiary hyperparathyroidism. <i>American Journal of Surgery</i> , 2008, 196, 13-18.	0.9	15
39	Embolization Therapy of Bone Metastases from Epithelial Thyroid Carcinoma: Effect on Symptoms and Serum Thyroglobulin. <i>Thyroid</i> , 2008, 18, 1277-1284.	2.4	23
40	The follow-up of patients with differentiated thyroid cancer and undetectable thyroglobulin (Tg) and Tg antibodies during ablation. <i>European Journal of Endocrinology</i> , 2008, 158, 77-83.	1.9	68
41	Improved Staging of Patients With Carcinoid and Islet Cell Tumors With <sup>18</sup> F-Dihydroxy-Phenyl-Alanine and <sup>11</sup> C-5-Hydroxy-Tryptophan Positron Emission Tomography. <i>Journal of Clinical Oncology</i> , 2008, 26, 1489-1495.	0.8	240
42	<sup>68</sup> Ge-Fluorodihydroxyphenylalanine PET in Neuroendocrine Tumors: Basic Aspects and Emerging Clinical Applications. <i>Journal of Nuclear Medicine</i> , 2008, 49, 573-586.	2.8	178
43	Manipulation of [ <sup>11</sup> C]-5-Hydroxytryptophan and <sup>68</sup> Ge-Fluoro-3,4-Dihydroxy-L-Phenylalanine Accumulation in Neuroendocrine Tumor Cells. <i>Cancer Research</i> , 2008, 68, 7183-7190.	0.4	54
44	<sup>18</sup> F-Dihydroxyphenylalanine PET in Patients with Biochemical Evidence of Medullary Thyroid Cancer: Relation to Tumor Differentiation. <i>Journal of Nuclear Medicine</i> , 2008, 49, 524-531.	2.8	116
45	<sup>111</sup> In-Octreotide Is Superior to <sup>123</sup> I-Metaiodobenzylguanidine for Scintigraphic Detection of Head and Neck Paragangliomas. <i>Journal of Nuclear Medicine</i> , 2008, 49, 1232-1237.	2.8	115
46	Comparison of <sup>11</sup> C-methionine PET and <sup>18</sup> F-fluorodeoxyglucose PET in differentiated thyroid cancer. <i>Nuclear Medicine Communications</i> , 2008, 29, 711-716.	0.5	10
47	Diagnostic Performance and Prognostic Value of Extravascular Retention of <sup>123</sup> I-Labeled Serum Amyloid P Component in Systemic Amyloidosis. <i>Journal of Nuclear Medicine</i> , 2007, 48, 865-872.	2.8	45
48	Detection of bone metastases in thyroid cancer patients: Bone scintigraphy or <sup>18</sup> F-FDG PET?. <i>Nuclear Medicine Communications</i> , 2007, 28, 597-602.	0.5	14
49	Immediate dynamic lymphoscintigraphy delivers no additional value to lymphoscintigraphy 3 hr after tracer injection in sentinel lymph node biopsy in breast cancer patients. <i>Journal of Surgical Oncology</i> , 2007, 95, 469-475.	0.8	10
50	Value of <sup>123</sup> I-Subtraction and Single-Photon Emission Computed Tomography in Addition to Planar <sup>99m</sup> Tc-MIBI Scintigraphy Before Parathyroid Surgery. <i>Surgery Today</i> , 2007, 37, 1033-1041.	0.7	9
51	A Sensitive Tg Assay or rhTSH Stimulated Tg: What's the Best in the Long-Term Follow-Up of Patients with Differentiated Thyroid Carcinoma?. <i>PLoS ONE</i> , 2007, 2, e816.	1.1	11
52	Staging of carcinoid tumours with <sup>18</sup> F-DOPA PET: a prospective, diagnostic accuracy study. <i>Lancet Oncology</i> , The, 2006, 7, 728-734.	5.1	234
53	Diagnostic Performance of <sup>123</sup> I-Labeled Serum Amyloid P Component Scintigraphy in Patients with Amyloidosis. <i>American Journal of Medicine</i> , 2006, 119, 355.e15-355.e24.	0.6	129
54	Myocardial perfusion quantification in patients suspected of cardiac syndrome X with positive and negative exercise testing: A [ <sup>13</sup> N]ammonia positron emission tomography study. <i>Nuclear Medicine Communications</i> , 2006, 27, 791-794.	0.5	17

#	ARTICLE	IF	CITATIONS
55	Optimal imaging of patients with ischaemic heart failure. <i>Nuclear Medicine Communications</i> , 2006, 27, 317-320.	0.5	0
56	Imaging Techniques in Nuclear Cardiology for the Assessment of Myocardial Viability. <i>International Journal of Cardiovascular Imaging</i> , 2006, 22, 63-80.	0.7	68
57	Prediction of functional recovery after revascularization in patients with chronic ischaemic left ventricular dysfunction: head-to-head comparison between 99mTc-sestamibi/18F-FDG DISA SPECT and 13N-ammonia/18F-FDG PET. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2006, 33, 716-723.	3.3	46
58	Prediction of functional recovery after revascularization in patients with coronary artery disease and left ventricular dysfunction by gated FDG-PET. <i>Journal of Nuclear Cardiology</i> , 2006, 13, 210-219.	1.4	52
59	Indium-111 <sup>99m</sup> Tc-Labeled Trastuzumab Scintigraphy in Patients With Human Epidermal Growth Factor Receptor 2 <sup>+</sup> Positive Metastatic Breast Cancer. <i>Journal of Clinical Oncology</i> , 2006, 24, 2276-2282.	0.8	270
60	Positron emission tomography with F-18-fluorodeoxyglucose in a combined staging strategy of esophageal cancer prevents unnecessary surgical explorations. <i>Journal of Gastrointestinal Surgery</i> , 2005, 9, 54-61.	0.9	84
61	Comparison of 99mTc-sestamibi/18F-FDG DISA SPECT with PET for the detection of viability in patients with coronary artery disease and left ventricular dysfunction. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2005, 32, 972-979.	3.3	27
62	Prognostic Value of the Standardized Uptake Value in Esophageal Cancer. <i>American Journal of Roentgenology</i> , 2005, 185, 436-440.	1.0	75
63	Esophageal Cancer: CT, Endoscopic US, and FDG PET for Assessment of Response to Neoadjuvant Therapy <sup>99m</sup> Tc Systematic Review. <i>Radiology</i> , 2005, 236, 841-851.	3.6	264
64	Repeated [ <sup>131</sup> I]Metaiodobenzylguanidine Therapy in Two Patients with Malignant Pheochromocytoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005, 90, 5888-5895.	1.8	25
65	Life expectancy in differentiated thyroid cancer: a novel approach to survival analysis. <i>Endocrine-Related Cancer</i> , 2005, 12, 273-280.	1.6	112
66	Carcinoid crisis after injection of 6-18F-fluorodihydroxyphenylalanine in a patient with metastatic carcinoid. <i>Journal of Nuclear Medicine</i> , 2005, 46, 1240-3.	2.8	34
67	Preclinical characterisation of 111 In-DTPA-trastuzumab. <i>British Journal of Pharmacology</i> , 2004, 143, 99-106.	2.7	140
68	Diagnostic <sup>131</sup> I scintigraphy in patients with differentiated thyroid cancer: No additional value of higher scan dose. <i>Annals of Nuclear Medicine</i> , 2004, 18, 641-6.	1.2	9
69	[ <sup>18</sup> F]FLT-PET in oncology: current status and opportunities. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2004, 31, 1659-1672.	3.3	266
70	Added value of attenuation-corrected Tc-99m tetrofosmin SPECT for the detection of myocardial viability: Comparison with FDG SPECT. <i>Journal of Nuclear Cardiology</i> , 2004, 11, 689-696.	1.4	19
71	Imatinib mesylate for the treatment of gastrointestinal stromal tumours: best monitored with FDG PET. <i>Nuclear Medicine Communications</i> , 2004, 25, 433-438.	0.5	118
72	<sup>18</sup> F-FLT PET for visualization of laryngeal cancer: comparison with <sup>18</sup> F-FDG PET. <i>Journal of Nuclear Medicine</i> , 2004, 45, 226-31.	2.8	70

#	ARTICLE	IF	CITATIONS
73	Selectivity of 18F-FLT and 18F-FDG for differentiating tumor from inflammation in a rodent model. <i>Journal of Nuclear Medicine</i> , 2004, 45, 695-700.	2.8	189
74	Is 18F-3'-fluoro-3'-deoxy-L-thymidine useful for the staging and restaging of non-small cell lung cancer?. <i>Journal of Nuclear Medicine</i> , 2004, 45, 1677-82.	2.8	45
75	Pitfalls of Positive Findings in Staging Esophageal Cancer With F-18-Fluorodeoxyglucose Positron Emission Tomography. <i>Annals of Surgical Oncology</i> , 2003, 10, 1100-1105.	0.7	49
76	Effect of attenuation correction on the interpretation of 99mTc-sestamibi myocardial perfusion scintigraphy: the impact of 1 year's experience. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2003, 30, 1505-1509.	3.3	23
77	Outcome in patients with differentiated thyroid cancer with negative diagnostic whole-body scanning and detectable stimulated thyroglobulin. <i>European Journal of Endocrinology</i> , 2003, 148, 589-596.	1.9	60
78	Better Yield of 18Fluorodeoxyglucose-Positron Emission Tomography in Patients with Metastatic Differentiated Thyroid Carcinoma during Thyrotropin Stimulation. <i>Thyroid</i> , 2002, 12, 381-387.	2.4	81
79	Uptake mechanisms of L-3-[125I]iodo-alpha-methyl-tyrosine in a human small-cell lung cancer cell line: comparison with L-1-[14C]tyrosine. <i>Nuclear Medicine Communications</i> , 2001, 22, 87-96.	0.5	8
80	Carbon-11 choline or FDG-PET for staging of oesophageal cancer?. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2001, 28, 1845-1849.	3.3	44
81	An automated synthesis module for preparation of l-3-[123I]iodo-alpha-methyl tyrosine. <i>Applied Radiation and Isotopes</i> , 2001, 55, 783-788.	0.7	6
82	Evaluation of 99mTc-MAMA-chrysamine G as an in vivo probe for amyloidosis. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2001, 8, 202-214.	1.4	14
83	Routine bone scintigraphy in primary staging of soft tissue sarcoma. <i>Cancer</i> , 2000, 89, 1726-1731.	2.0	33